IDP:FRA
Biogen Inc
€210.65
arrow_upward
+1.84%(+3.80) 1D
Oct 19, 7:59:38 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for IDP...
Open
€208.00
High
€210.65
Low
€207.65
Mkt. cap
34.67B
Avg. vol.
62.00
Volume
10.00
52-wk high
€213.00
52-wk low
€120.60
No. of employees
8K
Open
€208.00
High
€210.65
Low
€207.65
Mkt. cap
34.67B
Avg. vol.
62.00
Volume
10.00
52-wk high
€213.00
52-wk low
€120.60
No. of employees
8K
News stories
From web sources and news partners
Investing.com UK
·
8 hours ago
Biogen to present 76-week Empaveli data at kidney conference By Investing.com
Yahoo Finance
·
8 hours ago
Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week
ad-hoc-news.de
·
2 days ago
JPMorgan lifts target for Biogen stock to USD 300.00
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc
CEOChris Viehbacher
Employees7.5K
Founded1978
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websitebiogen.com